Treatment of early heart failure: an ACEI or a beta-blocker first?

Expert Opinion on Investigational Drugs
Ronnie Willenheimer

Abstract

The basis of modern chronic heart failure (CHF) treatment is a combination of optimum doses of a beta-blocker and an angiotensin-converting enzyme inhibitor (ACEI); however, patients cannot be started on full doses of both drugs and treatment has to be initiated one way or the other. By tradition and according to guideline recommendations, an ACEI is usually initiated first, followed by a beta-blocker after a varying time period based on clinical judgement. Early beta-blockade has several theoretical advantages, and two surrogate end point studies have indicated that initiation of CHF treatment with a beta-blocker may be superior to an ACEI. The Cardiac Insufficiency Bisoprolol III trial was the first trial investigating the optimum sequence of initiating treatment of CHF in terms of mortality and morbidity. The results indicated that, in stable, mildly to moderately symptomatic patients with systolic CHF, initiation of therapy with the beta-blocker bisoprolol followed by the ACEI enalapril was similarly efficacious to the opposite sequence in terms of combined mortality and all-cause hospitalisation. However, initiating therapy with bisoprolol showed a trend towards better survival, but also towards further worsening of CHF. T...Continue Reading

References

Jul 11, 1992·Lancet·M Packer
Jul 1, 1997·Journal of the American College of Cardiology·P A HeidenreichB M Massie
Aug 1, 1997·British Journal of Clinical Pharmacology·H Krum
Nov 5, 1997·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·T M WoleverM H Tan
Dec 31, 1997·Journal of the American College of Cardiology·B F Uretsky, R G Sheahan
Apr 5, 2000·International Journal of Cardiology·A C TeismanW H van Gilst
Aug 11, 2000·European Journal of Heart Failure·J G ClelandM Packer
Jun 2, 2001·The New England Journal of Medicine·M PackerUNKNOWN Carvedilol Prospective Randomized Cumulative Survival Study Group
Jan 17, 2002·The New England Journal of Medicine·H V HuikuriR J Myerburg
Nov 30, 2002·Lancet·J G F ClelandUNKNOWN Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology
Jun 9, 2004·European Journal of Heart Failure·Ronnie WillenheimerUNKNOWN CIBIS-III investigators
Apr 14, 2005·European Heart Journal·Michel KomajdaClaude Le Pen
Apr 16, 2005·Heart·Rebecca E LaneAnthony W C Chow

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.